American Shared Hospital Services — Q1 2023 Form 10-Q
Business context and period. The company provides Gamma Knife radiosurgery and proton beam radiation therapy (PBRT) equipment and services, reporting domestic and international segments. This unaudited filing covers the three months ended March 31, 2023, compared with Q1 2022; balance-sheet figures are compared with December 31, 2022.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $4.925 million | $4.847 million |
| Gross margin dollars (percentage of revenue) | $1.908 million (38.7%) | $2.067 million (42.6%) |
| Reported operating income | $98,000 | $600,000 |
| Net income | $100,000 | $394,000 |
| Net income attributable to ASHS | $188,000; $0.03 diluted EPS | $269,000; $0.04 diluted EPS |
| Cash provided by operating activities | $1.761 million | $259,000 |
| Capital expenditures | $209,000 | $66,000 |
- Revenue rose 1.6% year over year. PBRT revenue increased to $2.314 million from $2.039 million, while Gamma Knife revenue decreased to $2.611 million from $2.808 million.
- Gross margin percentage fell to 38.7% from 42.6%. Interest expense increased to $271,000 from $148,000; selling and administrative expense rose to $1.539 million from $1.319 million.
- Q1 cash flow from operations increased substantially year over year. Cash, cash equivalents and restricted cash totaled $13.201 million at March 31, 2023, up $748,000 from year-end; working capital was $14.317 million.
- Total reported long-term debt was $12.755 million, including current maturities; the $7 million revolving credit line was undrawn. The company reported compliance with its debt covenants. Debt facilities include floating-rate borrowings priced at LIBOR plus 3%; the company was working with its lender on a replacement base rate before the end of 2023.
- Current assets were $19.571 million and current liabilities were $5.254 million. Management said cash on hand, operating cash flow and other resources should cover scheduled debt obligations and working capital needs for the next 12 months. Approximately $2.094 million of principal and interest payments were scheduled over that period.
Material changes and operating drivers
- PBRT revenue grew despite treatment volume falling to 1,536 fractions from 1,628, primarily because of higher average reimbursement. Gamma Knife procedures declined to 293 from 329; lower volume reduced revenue, partly offset by higher average reimbursement from a more favorable commercial-payor mix.
- Management attributed lower earnings mainly to higher interest costs and increased selling and administrative spending supporting new business opportunities. Higher depreciation also weighed on results.
- Changes to useful-life and salvage-value estimates for an international Gamma Knife unit reduced Q1 net income by approximately $50,000, or $0.01 per diluted share. A previously disclosed estimate change for a domestic unit reduced Q1 net income by approximately $17,000. These estimates are expected to affect future periods.
Outlook, commitments and risks
- No specific financial guidance was provided. Management expects the new Puebla, Mexico radiation therapy site to begin operations in the second half of 2023, following regulatory approval; the Ecuador Gamma Knife upgrade was expected in mid-2023, pending approval.
- The company had $34 million in remaining commitments for two PBRT systems, which it was still seeking sites and financing for, and $16.228 million in Gamma Knife and LINAC commitments. It intends to finance substantially all of these equipment commitments, but said financing may not be available on acceptable terms. Total equipment service commitments were $15.168 million.
- The company warned that it could forfeit deposits tied to the two PBRT systems if it fails to secure customer agreements or an extension by the required delivery timeframe, no later than December 2023. Those deposits were previously impaired and written off.
- Management cited reimbursement changes, treatment-volume variability, financing availability, expansion and acquisition execution, and business and market conditions as risks. CMS’s Radiation Oncology Alternative Payment Model remains delayed indefinitely, with implementation timing and form uncertain.
- The filing added a risk concerning bank failures and financial-market instability: deposits may exceed FDIC insurance limits, and disruptions could restrict access to deposits or borrowing capacity.
- Related-party transactions with Elekta, a Gamma Knife manufacturer and 19% owner of the company’s GKF subsidiary, totaled $496,000 in Q1 2023. Legal proceedings were reported as none. Disclosure controls were deemed effective, with no material change in internal control over financial reporting reported.
Important facts for investors to verify
- Progress on financing, placement and delivery timing for the two PBRT systems, and potential consequences if required deadlines are not met.
- Whether expected Puebla operations and planned equipment upgrades proceed on schedule and receive necessary approvals.
- Trends in PBRT and Gamma Knife procedure volumes, payor mix and reimbursement, and whether improved PBRT revenue persists despite lower fractions.
- Interest-rate exposure and the transition from LIBOR, as well as covenant compliance and the timing of scheduled debt payments.
- Cash needs and financing plans for substantial equipment and service commitments relative to operating cash generation.
- Future earnings effects of the equipment-life and salvage-value estimates, and the continued collectability and timing of international receivables.